Herceptin Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Breast Cancer, Gastric Cancer, Others.); Application (Hospitals and clinics, Oncology Centers, Others.) and Geography
Herceptin is a monoclonal antibody, a cancer medication used in the treatment of breast cancer. Herceptin is called a "biologic" drug. It is made from a living organism and is also termed as a targeted therapy drug. Biologic drugs are very complex to make and very sensitive to change. A biosimilar is the biologic drug generic version. Herceptin is used as part of chemotherapy regimen for adjuvant treatment of lymph-node positive, protein-positive breast cancer and mainly administered intravenously in cancer patients; the dose of herceptin given to patients is evaluated based on patients' disease history and other physiological factors such as type of cancer or disease condition, height, and weight.
The rising prevalence of cancers such as breast cancer in women, rise in the cancer patient pool, and increasing demand for the targeted therapy are the major factor driving the growth of the global herceptin biosimilar market. Furthermore, the increasing prevalence of gastric cancers such as metastatic gastric cancer is the factor expected to propel the market's growth. Rising spending on research & development, changing lifestyle, increasing pollution, and adoption of smoking by the people will serve as fuel for the growth of the market. Due to the COVID-19 pandemic and lockdowns imposed by governments, the market experienced a decrease in sales. However, side effects associated with herceptin biosimilars such as pulmonary toxicity and embryo-fetal toxicity and the presence of alternatives are supposed to hinder the market growth over the forecast period.
The "Herceptin Biosimilars Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of herceptin biosimilars market with detailed market segmentation by type, and application. The herceptin biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in herceptin biosimilars market and offers key trends and opportunities in the market.
The herceptin biosimilars market is segmented on the basis of type, and application. On the basis of type, the market is segmented as breast cancer, gastric cancer, and others. On the basis of application, the market is segmented into hospitals and clinics, oncology centers, and others.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the herceptin biosimilars market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The herceptin biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting herceptin biosimilars market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the herceptin biosimilars market in these regions.
Get more information on this report :
The report covers key developments in the herceptin biosimilars market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from herceptin biosimilars market are anticipated to have lucrative growth opportunities in the future with the rising demand for herceptin biosimilars in the global market. Below mentioned is the list of few companies engaged in the herceptin biosimilars market.
The report also includes the profiles of key players in herceptin biosimilars market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Roche Holding AG
Samsung bioepis Co,.Ltd.
Merck & Co., Inc.
Gedeon Richter Plc
Genor Biopharma Company Ltd
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Amgen Inc.
2. AryoGen Biopharma
3. Roche Holding AG
4. Samsung bioepis Co,.Ltd.
5. Biocon Limited
6. Celltrion Inc.
7. Pfizer Inc.
8. Merck and Co., Inc.
9. Gedeon Richter Plc
10. Genor Biopharma Company Ltd